Tetraph Pharma (TTPH) Misses Q2 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tetraphase Pharmaceuticals (TTPH) Has Meaningful Catalysts Ahead, Baird Says
August 13, 2014 6:22 AM EDTBaird analyst Brian Skorney reiterated an Outperform rating and $21 price target on Tetraphase Pharmaceuticals (NASDAQ: TTPH) saying they are incrementally more bullish following yesterday's earnings report.
In the release, Tetraphase provided updates to its pipeline mentioning that the eravacycline trials continue to... More



